Updated on 25 April 2014
VCs have not yet invested heavily in biotech and there is a lack of confidence in the investor community about the investment climate in most parts of Asia and the capabilities of the entrepreneurs. What is very interesting is that the governments are now building cohesive ecosystems for biotech and multiple venture capital firms in order to help increase the levels of innovation, entrepreneurial zeal, industry- academia interface, and support funding and mentoring. This kind of an ecosystem is unparalleled and it is time that the investors' confidence is restored with better awareness and meaningful discussions.
According to Venkatadri Bobba, General Partner at Ventureast Fund Advisors India Ltd, the best is yet to come for BioPharma as there are no clear drug products from Human Genome Project as yet and there are no clear therapeutic paths to individual genomic based pharmacotherapy. The Playbook will be to enhance skills, leverage global expertise through partnerships, focus on biosimilars, bio-betters, or validated targets; and plan for success and failure.